Skip to main content
Equibles
SRRK logo

SRRK · Scholar Rock Holding Corp

Track SRRK — free

Use SRRK with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SRRK

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$52.52 -0.54 (-1.02%) At close · Aug 14
Market Cap
$6.40B
Shares
121.79M

Scholar Rock Holding Corp Earnings Call Transcripts

Every quarterly earnings call for Scholar Rock Holding Corp (SRRK) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Conference
Investor event
2026-08-12
Canaccord Genuity 46th Annual Growth Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Scholar Rock Q2 2026 Financial Results and Business Update Conference Call
Confident tone FDA review and PDUFA European MAA and launch readiness FSHD program (FORGE study)
Diluted EPS
$-0.84
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Jefferies Global 2026 Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Scholar Rock Holding Corp Q1 FY2026 Earnings Call
Confident tone FDA acceptance and PDUFA timeline for apitegromab BLA SMA launch readiness and patient population Anti-myostatin pipeline expansion beyond SMA
Revenue
$
Diluted EPS
$-0.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Scholar Rock Holding Corp Q4 FY2025 Earnings Call
Confident tone SMA commercial launch readiness SRK-439 and subQ formulation progress FSHD Phase 2 (FORGE) development
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Scholar Rock Holding Corp Q3 FY2025 Earnings Call
Positive tone SMA commercial opportunity FDA / Novo Nordisk Bloomington facility Apitegromab CRL and regulatory path
Diluted EPS
$-0.90
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Scholar Rock Holding Corp Q2 FY2025 Earnings Call
Confident tone Apitegromab regulatory approvals and commercial launch Apitegromab clinical profile in SMA FDA review and CDMO inspections
Diluted EPS
$-0.98
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Scholar Rock Holding Corp Q1 FY2025 Earnings Call
Confident tone Apitegromab for SMA SRK-439 development Regulatory progress and launch
Diluted EPS
$-0.67
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Scholar Rock Holding Corp Q4 FY2024 Earnings Call
Confident tone SRK-439 anti-myostatin development Apitegromab SAPPHIRE trial results Regulatory submissions and milestones
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Scholar Rock Holding Corp Q3 FY2024 Earnings Call
Confident tone Apitegromab efficacy and safety SAPPHIRE Phase 3 results SRK-439 cardiometabolic/obesity pipeline
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Scholar Rock Holding Corp Q2 FY2024 Earnings Call
Confident tone SRK-439 / EMBRAZE in obesity Apitegromab SAPPHIRE Phase 3 readout TOPAZ long-term data
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Scholar Rock Holding Corp Q1 FY2024 Earnings Call
Diluted EPS
$-0.59
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Scholar Rock Holding Corp Q4 FY2023 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Scholar Rock Holding Corp Q3 FY2023 Earnings Call
Diluted EPS
$-0.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Scholar Rock Holding Corp Q2 FY2023 Earnings Call
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Scholar Rock Holding Corp Q1 FY2023 Earnings Call
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Scholar Rock Holding Corp Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Scholar Rock Holding Corp Q3 FY2022 Earnings Call
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Scholar Rock Holding Corp Q2 FY2022 Earnings Call
Diluted EPS
$-1.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Scholar Rock Holding Corp Q1 FY2022 Earnings Call
Revenue
$33.19M
▲ 605% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-07
Scholar Rock Holding Corp Q4 FY2021 Earnings Call
Revenue
$4.05M*
▲ 17.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q2
2020-08-07
Scholar Rock Holding Corp Q2 FY2020 Earnings Call
Revenue
$3.90M
▼ 22.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–23 of 23 earnings calls
Key facts CIK 1727196 CUSIP 80706P103 13F (30d) 293 filings 291 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)